Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study

OBJECTIVES: We aimed to evaluate COVID-19 messenger RNA vaccine effectiveness during the Delta- and Omicron-predominant periods in Japan. METHODS: We conducted a population-based cohort study among individuals aged 16–64 years during two periods: the Delta-predominant period (July 1–December 31, 202...

Descripción completa

Detalles Bibliográficos
Autores principales: Mimura, Wataru, Ishiguro, Chieko, Maeda, Megumi, Murata, Fumiko, Fukuda, Haruhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547653/
https://www.ncbi.nlm.nih.gov/pubmed/36220547
http://dx.doi.org/10.1016/j.ijid.2022.10.001
Descripción
Sumario:OBJECTIVES: We aimed to evaluate COVID-19 messenger RNA vaccine effectiveness during the Delta- and Omicron-predominant periods in Japan. METHODS: We conducted a population-based cohort study among individuals aged 16–64 years during two periods: the Delta-predominant period (July 1–December 31, 2021) and the Omicron-predominant period (January 1–March 29, 2022). RESULTS: When comparing individuals who were vaccinated with those who were unvaccinated, the effectiveness of a second dose against symptomatic infection was 89.8% (95% confidence interval [CI]: 80.5–94.7%) during the Delta-predominant period and 21.2% (95% CI: 11.0–30.3%) during the Omicron-predominant period. The effectiveness of a third dose against symptomatic infection was 71.8% (95% CI: 60.1–80.1%) during the Omicron-predominant period. CONCLUSION: Vaccine effectiveness against symptomatic infection decreased during the Omicron-predominant period but was maintained by a third dose.

Ejemplares similares